News

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking ...
New indication added for selection of patients for amyloid-directed therapiesQuantitative image analysis addedPrevious limitations of use removed BOSTON, July 1, 2025 /PRNewswire/ -- Life Molecular ...
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat reports. One ...
Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.
Equities researchers at Lifesci Capital issued their Q2 2025 EPS estimates for Cogent Biosciences in a research report issued to clients and investors on Monday, June 30th. Lifesci Capital analyst S.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.
Feeling a little down? Discover how you can boost your happiness and improve your health by harnessing the powerful benefits of endorphins. With easy methods like exercise, laughter, and connection at ...
MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® ...
The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.
Picture this: It’s 3 PM, and you’re crashing harder than a ... Gymnema sylvestre targets sugar receptors to reduce cravings while supporting pancreatic beta cell function. Bitter melon provides ...